EN-374 granted rare pediatric disease, orphan drug designations for chronic granulomatous disease

Published Date: 16 Feb 2025

Ensoma's lead program, EN-374, has been granted a pair of FDA designations for the treatment of X-linked chronic granulomatous disease.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions

2.

Chris Hoy reveals that he has terminal cancer?here's how to spot early signs of prostate cancer

3.

Frontline EGFR/VEGF Inhibition Slows Advanced EGFR-Positive Lung Cancer

4.

FDA Bans Red Dye No. 3 From Foods, Ingested Drugs

5.

In MDS at Lower Risk, Novel Therapy Diminished Transfusion Dependency.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot